**Question:** All of the following are associated with good prognosis in childhood leukemia except:

A. Abnormal karyotype
B. Severe cytopenias
C. Resistance to therapy
D. Extramedullary involvement

**Core Concept:** Good prognosis in childhood leukemia is typically associated with the following factors:

1. Absence of specific genetic mutations or abnormalities in the karyotype, which can indicate a higher risk of disease progression or resistance to treatment.
2. Presence of mild to moderate cytopenias, which can indicate a milder form of leukemia.
3. Sensitivity to therapy, which indicates that the leukemia cells are responsive to treatment.

**Why the Correct Answer is Right:**

D. Extramedullary involvement (EMH) is not considered a good prognosis factor in childhood leukemia. Extramedullary hematopoiesis refers to the production of blood cells outside the bone marrow, often found in organs like liver, spleen, or lymph nodes. In leukemia, the presence of EMH indicates that the disease has spread beyond the bone marrow, leading to a poorer prognosis.

**Why Each Wrong Option is Incorrect:**

A. Abnormal karyotype: While some abnormal karyotypes are associated with a poorer prognosis, others can indicate a milder form of leukemia, making this option more complex than the correct answer.

B. Severe cytopenias: Although severe cytopenias can indicate a more aggressive leukemia, mild to moderate cytopenias are typically associated with a better prognosis.

C. Resistance to therapy: Resistance to therapy is generally considered a poor prognostic factor, but not all forms of resistance are unfavorable. For example, some patients may initially respond to treatment but develop therapy resistance later. This option is more complex than the correct answer.

**Clinical Pearl:**

In childhood leukemia, assessing the extent of extramedullary involvement and the presence of specific genetic mutations can help guide treatment decisions and predict prognosis. Understanding these factors is crucial for healthcare professionals treating pediatric leukemia patients.